Clinical development failure
Product candidates may not show sufficient safety or efficacy in trials.
- Scope
- RLYB116, RLYB114, RLYB332 and other pipeline assets
- Materiality
- high
Rallybio Corp
Rallybio Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with significant unmet medical need. Its portfolio includes product candidates and partnered programs aimed at conditions such as complement-mediated disorders and fetal/neonatal immune diseases, developed through internal research and collaborations.
−3 842,9 %
−1 046,4 %
+34,9 %
14.50
14.50
| % | |
|---|---|
| Clinical-stage drug candidates | 85% Proprietary therapeutic programs in development for rare diseases and immune-mediated disorders. |
| Collaboration and license revenue | 10% Research, data collection, and data submission services under partner agreements. |
| Joint venture and partnered discovery | 5% Shared development efforts for small molecule therapeutics and related technologies. |
Rallybio does not sell approved products; its direct counterparties are pharmaceutical partners, research...
- Pharmaceutical collaboration partnersprimary
Partners such as Johnson & Johnson and prior licensors that pay for research, data, or development rights.
- Clinical trial participants and investigatorsprimary
Patients, sites, and investigators involved in studies supporting development programs like FNAIT and complement disorders.
- Rare disease prescribersemerging
Specialty physicians who would use approved therapies for conditions such as PNH or gMG.
- Healthcare institutionsemerging
Hospitals and specialty centers that would administer or support treatment in rare disease settings.
Rallybio is headquartered in the United States and operates as a U.S.-based development company...
- •Headquartered in the United States
- •Clinical and research activities are centered on U.S.-based operations
- •Worldwide rights to some programs expand potential market reach
- •Partnered development can involve non-U.S. collaborators
- •Future commercialization would require multi-region sales infrastructure
Rallybio’s strategy is to advance rare disease programs through clinical development, protect and expand its...
01
Advance lead clinical programsshort-term
Clinical proof-of-concept is the main driver of value for a pre-commercial biotech.
02
Pursue collaborations and licensingshort-term
Partnerships can provide funding, data access, and development leverage.
03
Build commercialization readinessmedium-term
Approved products would require sales, marketing, and distribution capabilities.
04
Strengthen IP and supply chainmedium-term
Patent protection and manufacturing access are critical in rare disease drug development.
Rallybio faces the core risks of a clinical-stage biotech: program failure, regulatory setbacks, and the need for...
Regulatory approval risk
Even successful candidates must clear FDA and other regulatory hurdles.
- Scope
- Future commercialization of rare disease therapies
- Materiality
- high
Financing risk
The company has no product sales and needs additional funding to continue.
- Scope
- Operating runway and development programs
- Materiality
- high
Competitive pressure
Large pharma and biotech firms can outspend Rallybio in development and commercialization.
- Scope
- PNH and gMG-related complement inhibitor markets
- Materiality
- high
Intellectual property risk
Patent scope, validity, and expiry determine future exclusivity and pricing power.
- Scope
- Pipeline candidates and licensed technologies
- Materiality
- high
Partner dependence
Collaborations and in-licensed rights are important to the pipeline and revenue.
- Scope
- J&J collaboration, prior Sobi and Sanofi rights, Recursion JV
- Materiality
- medium
Collaboration and license revenue recognition
Affects timing and volatility of reported revenue
Equity-linked collaboration consideration
Can shift revenue recognition across periods
Research and development expense
Major determinant of reported earnings and cash burn
Joint venture accounting
Can reduce earnings even when cash outflow is limited
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
PALISADE BIO, INC.
PALI · Biological Products, (No Diagnostic Substances)
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
INOVIO PHARMACEUTICALS, INC.
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
MUSTANG BIO, INC.
MBIO · Pharmaceutical Preparations
: 29/04/2026